Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Nvidia added positions in struggling rival Intel ( INTC ), chip design software maker Synopsys ( SNPS ), and Finnish telecom Nokia ( NOK ). Synopsys shares climbed about 6% in recent trading, while ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

If you are leasing a car, what’s the point of paying thousands of dollars due at lease signing? My contract says tax, title, fees and licensing — but then wouldn’t I have to pay that again at the end ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

SPOILER ALERT: This article contains major spoilers for Osgood Perkins‘ “Keeper,” now playing in theaters. Director Osgood Perkins has given us not one, but two twisted horror movies this year that ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...